Stockwatch: Orchestrating investors in the dark
This article was originally published in Scrip
The history of the biotechnology sector is punctuated by binary events. These are mostly clinical or regulatory developments that result in big share price moves. Until recently, an IPO acted like a binary event with big upward share price moves on the first day of trading. What most investors do not realize is that that IPOs can be the result of months or even years of careful orchestration in order to get the story presented to investors straight, even if it is highly spun.
You may also be interested in...
As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.
Stock market reaction to the first day’s news from the 38th J.P. Morgan Healthcare conference in San Francisco was negative, probably because expectations for a continuation of December’s bumper M&A bonanza were too high.
With the 38th J.P. Morgan Healthcare conference about to start in San Francisco, expectations in the investment community are naturally high. This is after a year when the NASDAQ Biotech Index approached its 2015 all-time high, fueled by the acquisitions of biotech companies by pharma companies.